DRG Market Assessment reports

Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…

Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…

Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…

Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…

Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…

Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…

Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key GIST patient populations covering 171 countries and more than 99% of the…

Clarivate’s Epidemiology’s coverage of GIST comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of GIST for each country, as…

The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and…

Gastrointestinal stromal tumors (GISTs) are rare cancers that belong to a group of cancers known as soft tissue sarcomas, which develop in supporting and connective tissues. GISTs account for…